{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:12:08Z","timestamp":1794370328432,"version":"4.9.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41584-023-01054-9","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:02:00Z","timestamp":1701856920000},"page":"48-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":181,"title":["Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress"],"prefix":"10.1038","volume":"20","author":[{"given":"Xin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-1729","authenticated-orcid":false,"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-9376","authenticated-orcid":false,"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg, I. E. et al. Idiopathic inflammatory myopathies. Nat. Rev. Dis. Prim. 7, 86 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1054_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290\u2013302 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1054_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato, S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571\u20131576 (2005).","journal-title":"Arthritis Rheum."},{"key":"1054_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer, R. D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J. Am. Acad. Dermatol. 46, 626\u2013636 (2002).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1054_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","volume":"30","author":"AL Mammen","year":"2020","unstructured":"Mammen, A. L., Allenbach, Y., Stenzel, W. & Benveniste, O. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscul. Disord. 30, 70\u201392 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1054_CR6","doi-asserted-by":"publisher","first-page":"R214","DOI":"10.1186\/ar3547","volume":"13","author":"Y Muro","year":"2011","unstructured":"Muro, Y., Sugiura, K., Hoshino, K., Akiyama, M. & Tamakoshi, K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res. Ther. 13, R214 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1054_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001202","volume":"6","author":"N Nishina","year":"2020","unstructured":"Nishina, N., Sato, S., Masui, K., Gono, T. & Kuwana, M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 6, e001202 (2020).","journal-title":"RMD Open."},{"key":"1054_CR8","doi-asserted-by":"publisher","first-page":"837024","DOI":"10.3389\/fmed.2022.837024","volume":"9","author":"H So","year":"2022","unstructured":"So, H. et al. Seasonal effect on disease onset and presentation in anti-MDA5 positive dermatomyositis. Front. Med. 9, 837024 (2022).","journal-title":"Front. Med."},{"key":"1054_CR9","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","volume":"20","author":"S Toquet","year":"2021","unstructured":"Toquet, S. et al. The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun. Rev. 20, 102788 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1054_CR10","doi-asserted-by":"publisher","first-page":"937667","DOI":"10.3389\/fimmu.2022.937667","volume":"13","author":"A Tonutti","year":"2022","unstructured":"Tonutti, A. et al. Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: a case report and systematic literature review. Front. Immunol. 13, 937667 (2022).","journal-title":"Front. Immunol."},{"key":"1054_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3899\/jrheum.220259","volume":"49","author":"T Kitajima","year":"2022","unstructured":"Kitajima, T. et al. Antimelanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines. J. Rheumatol. 49, 1158\u20131162 (2022).","journal-title":"J. Rheumatol."},{"key":"1054_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.55563\/clinexprheumatol\/44kaji","volume":"39","author":"Y Kondo","year":"2021","unstructured":"Kondo, Y. et al. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still\u2019s disease. Clin. Exp. Rheumatol. 39, 631\u2013638 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","volume":"293","author":"Q Jin","year":"2023","unstructured":"Jin, Q. et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti\u2010MDA5\u2010positive dermatomyositis. J. Intern. Med. 293, 494\u2013507 (2023).","journal-title":"J. Intern. Med."},{"key":"1054_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino, D., Chung, L., Zwerner, J., Rosen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25\u201334 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1054_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","volume":"78","author":"DJB Kurtzman","year":"2018","unstructured":"Kurtzman, D. J. B. & Vleugels, R. A. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J. Am. Acad. Dermatol. 78, 776\u2013785 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1054_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jamadermatol.2017.5462","volume":"154","author":"A Combalia","year":"2018","unstructured":"Combalia, A., Giavedoni, P., Tamez, L., Grau-Junyent, J. M. & Mascar\u00f3, J. M. Jr. Bosentan for cutaneous ulcers in anti-MDA5 dermatomyositis. JAMA Dermatol. 154, 371\u2013373 (2018).","journal-title":"JAMA Dermatol."},{"key":"1054_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3988\/jcn.2020.16.1.160","volume":"16","author":"HK Min","year":"2020","unstructured":"Min, H. K. et al. Refractory digital ulcers treated by botulinum toxin and endothelin receptor-1 antagonist in anti-MDA5-antibody-positive dermatomyositis. J. Clin. Neurol. 16, 160 (2020).","journal-title":"J. Clin. Neurol."},{"key":"1054_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","volume":"67","author":"NS Narang","year":"2015","unstructured":"Narang, N. S., Casciola-Rosen, L., Li, S., Chung, L. & Fiorentino, D. F. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 67, 667\u2013672 (2015).","journal-title":"Arthritis Care Res."},{"key":"1054_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaad.2019.05.053","volume":"81","author":"K Chanprapaph","year":"2019","unstructured":"Chanprapaph, K., Udompanich, S., Visessiri, Y., Ngamjanyaporn, P. & Suchonwanit, P. Nonscarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses. J. Am. Acad. Dermatol. 81, 1319\u20131329 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1054_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/art.40491","volume":"70","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. Differential clinical associations of anti\u2013nuclear matrix protein 2 autoantibodies in patients with idiopathic inflammatory myopathies. Arthritis Rheumatol. 70, 1288\u20131297 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1054_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall, J. C. et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 65, 1307\u20131315 (2013).","journal-title":"Arthritis Care Res."},{"key":"1054_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","volume":"150","author":"A Valenzuela","year":"2014","unstructured":"Valenzuela, A., Chung, L., Casciola-Rosen, L. & Fiorentino, D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 150, 724\u2013729 (2014).","journal-title":"JAMA Dermatol."},{"key":"1054_CR23","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/rheumatology\/keaa821","volume":"60","author":"U Rathore","year":"2021","unstructured":"Rathore, U., Haldule, S. & Gupta, L. Psoriasiform rashes as the first manifestation of anti-MDA5 associated myositis. Rheumatology 60, 3483\u20133483 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR24","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front. Immunol. 12, 773352 (2021).","journal-title":"Front. Immunol."},{"key":"1054_CR25","doi-asserted-by":"publisher","first-page":"152231","DOI":"10.1016\/j.semarthrit.2023.152231","volume":"62","author":"H Xie","year":"2023","unstructured":"Xie, H. et al. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review. Semin. Arthritis Rheum. 62, 152231 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1054_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono, T. et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49, 1713\u20131719 (2010).","journal-title":"Rheumatology"},{"key":"1054_CR27","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","volume":"32","author":"F Chen","year":"2012","unstructured":"Chen, F., Wang, D., Shu, X., Nakashima, R. & Wang, G. Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol. Int. 32, 3909\u20133915 (2012).","journal-title":"Rheumatol. Int."},{"key":"1054_CR28","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli, A. et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin. Exp. Rheumatol. 32, 891\u2013897 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen, Z. et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 65, 1316\u20131324 (2013).","journal-title":"Arthritis Care Res."},{"key":"1054_CR30","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","volume":"59","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology 59, 2829\u20132837 (2020).","journal-title":"Rheumatology"},{"key":"1054_CR31","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","volume":"55","author":"H Chino","year":"2016","unstructured":"Chino, H. et al. Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage. Intern. Med. 55, 2241\u20132246 (2016).","journal-title":"Intern. Med."},{"key":"1054_CR32","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2169\/internalmedicine.2328-18","volume":"58","author":"H Chino","year":"2019","unstructured":"Chino, H. et al. Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: rapidly progressive perilobular opacity. Intern. Med. 58, 2605\u20132613 (2019).","journal-title":"Intern. Med."},{"key":"1054_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003150","volume":"9","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease. RMD Open. 9, e003150 (2023).","journal-title":"RMD Open."},{"key":"1054_CR34","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s10067-019-04918-2","volume":"39","author":"M Zhou","year":"2020","unstructured":"Zhou, M. et al. Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin. Rheumatol. 39, 1919\u20131927 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002770","volume":"9","author":"K Abe","year":"2023","unstructured":"Abe, K. et al. Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study. RMD Open. 9, e002770 (2023).","journal-title":"RMD Open."},{"key":"1054_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","volume":"35","author":"X Ma","year":"2016","unstructured":"Ma, X. et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin. Rheumatol. 35, 489\u2013493 (2016).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR37","doi-asserted-by":"publisher","first-page":"928861","DOI":"10.3389\/fimmu.2022.928861","volume":"13","author":"S Zhou","year":"2022","unstructured":"Zhou, S. et al. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis\/clinically amyopathic dermatomyositis: a retrospective study. Front. Immunol. 13, 928861 (2022).","journal-title":"Front. Immunol."},{"key":"1054_CR38","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","volume":"38","author":"S Li","year":"2019","unstructured":"Li, S. et al. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clin. Rheumatol. 38, 2171\u20132179 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR39","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1093\/rheumatology\/keab637","volume":"60","author":"R Sakamoto","year":"2021","unstructured":"Sakamoto, R. et al. Myxovirus resistance protein 1-expressing fatal myocarditis in a patient with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 60, e450\u2013e452 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR40","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1093\/rheumatology\/kead008","volume":"62","author":"A Roeser","year":"2023","unstructured":"Roeser, A. et al. Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease. Rheumatology 62, e246\u2013e248 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR41","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1097\/RHU.0000000000001756","volume":"28","author":"PA Olivo Pallo","year":"2022","unstructured":"Olivo Pallo, P. A. et al. Characterization of patients with dermatomyositis according to anti-melanoma differentiation-associated gene-5 autoantibodies in centers from 3 Latin American countries: a cohort study. J. Clin. Rheumatol. 28, e444\u2013e448 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"1054_CR42","doi-asserted-by":"publisher","first-page":"802753","DOI":"10.3389\/fmed.2021.802753","volume":"8","author":"Z Xu","year":"2021","unstructured":"Xu, Z. et al. Spontaneous intramuscular hemorrhage in anti-MDA5 positive dermatomyositis: a case series and literature review. Front. Med. 8, 802753 (2021).","journal-title":"Front. Med."},{"key":"1054_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res. Ther. 19, 259 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1054_CR44","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 1955\u20131964 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2169\/internalmedicine.1516-18","volume":"58","author":"N Sakamoto","year":"2019","unstructured":"Sakamoto, N. et al. Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis. Intern. Med. 58, 837\u2013841 (2019).","journal-title":"Intern. Med."},{"key":"1054_CR46","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193\u20132200 (2009).","journal-title":"Arthritis Rheum."},{"key":"1054_CR47","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","volume":"78","author":"F Espinosa-Ortega","year":"2019","unstructured":"Espinosa-Ortega, F. et al. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 78, 858\u2013860 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR48","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","volume":"32","author":"J Damoiseaux","year":"2022","unstructured":"Damoiseaux, J., Mammen, A. L., Piette, Y., Benveniste, O. & Allenbach, Y. 256th ENMC international workshop: myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8\u201310 October 2021. Neuromuscul. Disord. 32, 594\u2013608 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"1054_CR49","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 95, e70\u2013e78 (2020).","journal-title":"Neurology"},{"key":"1054_CR50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.42308","volume":"75","author":"L Xu","year":"2023","unstructured":"Xu, L. et al. Identification of three different phenotypes in anti\u2013melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol. 75, 609\u2013619 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1054_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","volume":"40","author":"Q Yang","year":"2022","unstructured":"Yang, Q. et al. Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses. Clin. Exp. Rheumatol. 40, 304\u2013308 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR52","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.autrev.2017.07.021","volume":"16","author":"S Gao","year":"2017","unstructured":"Gao, S. et al. Using multi-omics methods to understand dermatomyositis\/polymyositis. Autoimmun. Rev. 16, 1044\u20131048 (2017).","journal-title":"Autoimmun. Rev."},{"key":"1054_CR53","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s10067-023-06624-6","volume":"42","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis. Clin. Rheumatol. 42, 2145\u20132154 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita, T. et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br. J. Dermatol. 176, 395\u2013402 (2017).","journal-title":"Br. J. Dermatol."},{"key":"1054_CR55","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao, H. et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 64, 1602\u20131610 (2012).","journal-title":"Arthritis Care Res."},{"key":"1054_CR56","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","volume":"56","author":"S Sakamoto","year":"2018","unstructured":"Sakamoto, S. et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respir. Investig. 56, 464\u2013472 (2018).","journal-title":"Respir. Investig."},{"key":"1054_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","volume":"62","author":"Y-T Xu","year":"2023","unstructured":"Xu, Y.-T. et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology 62, 397\u2013406 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","volume":"23","author":"S Sato","year":"2013","unstructured":"Sato, S., Kuwana, M., Fujita, T. & Suzuki, Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 23, 496\u2013502 (2013).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR59","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/rheumatology\/keab268","volume":"61","author":"M Chen","year":"2022","unstructured":"Chen, M. et al. Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis. Rheumatology 61, 430\u2013439 (2022).","journal-title":"Rheumatology"},{"key":"1054_CR60","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12890-022-02106-8","volume":"22","author":"T Liu","year":"2022","unstructured":"Liu, T. et al. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis. BMC Pulm. Med. 22, 316 (2022).","journal-title":"BMC Pulm. Med."},{"key":"1054_CR61","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10067-023-06542-7","volume":"42","author":"M Li","year":"2023","unstructured":"Li, M. et al. Elevated platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with polymyositis\/dermatomyositis: a retrospective study. Clin. Rheumatol. 42, 1615\u20131624 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR62","doi-asserted-by":"publisher","first-page":"117321","DOI":"10.1016\/j.cca.2023.117321","volume":"543","author":"S Lin","year":"2023","unstructured":"Lin, S. et al. Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis. Clin. Chim. Acta 543, 117321 (2023).","journal-title":"Clin. Chim. Acta"},{"key":"1054_CR63","doi-asserted-by":"publisher","first-page":"845988","DOI":"10.3389\/fimmu.2022.845988","volume":"13","author":"Y Zuo","year":"2022","unstructured":"Zuo, Y. et al. Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome. Front. Immunol. 13, 845988 (2022).","journal-title":"Front. Immunol."},{"key":"1054_CR64","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51, 1563\u20131570 (2012).","journal-title":"Rheumatology"},{"key":"1054_CR65","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","volume":"38","author":"L Jiang","year":"2019","unstructured":"Jiang, L. et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin. Rheumatol. 38, 1655\u20131663 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR66","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","volume":"61","author":"J So","year":"2022","unstructured":"So, J. et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology 61, 4437\u20134444 (2022).","journal-title":"Rheumatology"},{"key":"1054_CR67","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/crj.13616","volume":"17","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti\u2010MDA5 antibody\u2010positive dermatomyositis related interstitial lung disease. Clin. Respiratory J. 17, 507\u2013515 (2023).","journal-title":"Clin. Respiratory J."},{"key":"1054_CR68","doi-asserted-by":"publisher","first-page":"628128","DOI":"10.3389\/fcell.2021.628128","volume":"9","author":"L Liang","year":"2021","unstructured":"Liang, L. et al. Aberrantly expressed galectin-9 Is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease. Front. Cell Dev. Biol. 9, 628128 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1054_CR69","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A Nishioka","year":"2019","unstructured":"Nishioka, A. et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod. Rheumatol. 29, 814\u2013820 (2019).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cei.13404","volume":"199","author":"QL Peng","year":"2020","unstructured":"Peng, Q. L. et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Clin. Exp. Immunol. 199, 314\u2013325 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"1054_CR71","doi-asserted-by":"publisher","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","volume":"40","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease. Clin. Exp. Rheumatol. 40, 292\u2013297 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR72","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/imj.12754","volume":"45","author":"F Chen","year":"2015","unstructured":"Chen, F. et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study. Intern. Med. J. 45, 641\u2013647 (2015).","journal-title":"Intern. Med. J."},{"key":"1054_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22978","volume":"33","author":"Y Ye","year":"2019","unstructured":"Ye, Y., Fu, Q., Wang, R., Guo, Q. & Bao, C. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J. Clin. Lab. Anal. 33, e22978 (2019).","journal-title":"J. Clin. Lab. Anal."},{"key":"1054_CR74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3109\/14397595.2013.844390","volume":"24","author":"M Nara","year":"2014","unstructured":"Nara, M. et al. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod. Rheumatol. 24, 633\u2013636 (2014).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR75","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/joim.13154","volume":"289","author":"T Shimizu","year":"2020","unstructured":"Shimizu, T. et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis. J. Intern. Med. 289, 206\u2013220 (2020).","journal-title":"J. Intern. Med."},{"key":"1054_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2018.06.012","volume":"141","author":"T Takada","year":"2018","unstructured":"Takada, T. et al. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. Respir. Med. 141, 7\u201313 (2018).","journal-title":"Respir. Med."},{"key":"1054_CR77","first-page":"373","volume":"50","author":"J Hannah","year":"2023","unstructured":"Hannah, J. et al. A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease. J. Rheumatol. 50, 373\u2013383 (2023).","journal-title":"J. Rheumatol."},{"key":"1054_CR78","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.24993","volume":"75","author":"W Jiang","year":"2023","unstructured":"Jiang, W. et al. Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: a single cohort study. Arthritis Care Res. 75, 1175\u20131182 (2023).","journal-title":"Arthritis Care Res."},{"key":"1054_CR79","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/rheumatology\/keac525","volume":"62","author":"X Lian","year":"2023","unstructured":"Lian, X. et al. Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease. Rheumatology 62, 1910\u20131919 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR80","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","volume":"76","author":"J Svensson","year":"2017","unstructured":"Svensson, J., Holmqvist, M., Lundberg, I. E. & Arkema, E. V. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study. Ann. Rheum. Dis. 76, 1803\u20131808 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR81","doi-asserted-by":"publisher","first-page":"791348","DOI":"10.3389\/fimmu.2021.791348","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front. Immunol. 12, 791348 (2021).","journal-title":"Front. Immunol."},{"key":"1054_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25509-3","volume":"12","author":"SE Chang","year":"2021","unstructured":"Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021).","journal-title":"Nat. Commun."},{"key":"1054_CR83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41927-022-00271-1","volume":"6","author":"K Anderle","year":"2022","unstructured":"Anderle, K. et al. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol. 6, 42 (2022).","journal-title":"BMC Rheumatol."},{"key":"1054_CR84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s42399-022-01357-0","volume":"5","author":"S Wang","year":"2022","unstructured":"Wang, S., Noumi, B., Malik, F. & Wang, S. A rare case of MDA-5-positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease following COVID-19 mRNA vaccination \u2014 a case report. SN Compr. Clin. Med. 5, 18 (2022).","journal-title":"SN Compr. Clin. Med."},{"key":"1054_CR85","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1111\/jdv.18653","volume":"37","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. A case of anti-MDA5-positive dermatomyositis after inactivated COVID-19 vaccine. J. Eur. Acad. Dermatol. Venereol. 37, e127\u2013e129 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1054_CR86","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00296-022-05176-3","volume":"42","author":"MT Holzer","year":"2022","unstructured":"Holzer, M. T. et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol. Int. 42, 2267\u20132276 (2022).","journal-title":"Rheumatol. Int."},{"key":"1054_CR87","doi-asserted-by":"publisher","first-page":"2001618","DOI":"10.1183\/13993003.01618-2020","volume":"56","author":"M Giannini","year":"2020","unstructured":"Giannini, M. et al. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur. Respir. J. 56, 2001618 (2020).","journal-title":"Eur. Respir. J."},{"key":"1054_CR88","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1136\/annrheumdis-2020-218594","volume":"81","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Du, G., Zhang, G., Matucci-Cerinic, M. & Furst, D. E. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann. Rheum. Dis. 81, e192\u2013e192 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11926-021-01023-9","volume":"23","author":"A Saud","year":"2021","unstructured":"Saud, A., Naveen, R., Aggarwal, R. & Gupta, L. COVID-19 and myositis: what we know so far. Curr. Rheumatol. Rep. 23, 63 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1054_CR90","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/art.38137","volume":"65","author":"FW Miller","year":"2013","unstructured":"Miller, F. W. et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 65, 3239\u20133247 (2013).","journal-title":"Arthritis Rheum."},{"key":"1054_CR91","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","volume":"75","author":"S Rothwell","year":"2016","unstructured":"Rothwell, S. et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann. Rheum. Dis. 75, 1558\u20131566 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR92","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell, S. et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann. Rheum. Dis. 78, 996\u20131002 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR93","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1002\/art.34657","volume":"64","author":"T Gono","year":"2012","unstructured":"Gono, T. et al. Brief report: association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64, 3736\u20133740 (2012).","journal-title":"Arthritis Rheum."},{"key":"1054_CR94","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.170165","volume":"44","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J. Rheumatol. 44, 1389\u20131393 (2017).","journal-title":"J. Rheumatol."},{"key":"1054_CR95","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/tan.13171","volume":"90","author":"JM Lin","year":"2017","unstructured":"Lin, J. M. et al. Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population. HLA 90, 354\u2013359 (2017).","journal-title":"HLA"},{"key":"1054_CR96","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","volume":"49","author":"EH Kang","year":"2019","unstructured":"Kang, E. H. et al. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Semin. Arthritis Rheum. 49, 283\u2013287 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1054_CR97","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y Kochi","year":"2018","unstructured":"Kochi, Y. et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann. Rheum. Dis. 77, 602\u2013611 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR98","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1093\/rheumatology\/kead006","volume":"62","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology 62, 2320\u20132324 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR99","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH Zhang","year":"2019","unstructured":"Zhang, S. H. et al. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br. J. Dermatol. 180, 1090\u20131098 (2019).","journal-title":"Br. J. Dermatol."},{"key":"1054_CR100","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/keac234","volume":"62","author":"N Shen","year":"2023","unstructured":"Shen, N. et al. MDA5 expression is associated with TGF-\u03b2-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis. Rheumatology 62, 373\u2013383 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR101","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","volume":"24","author":"Y Zaizen","year":"2023","unstructured":"Zaizen, Y. et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis. Respir. Res. 24, 86 (2023).","journal-title":"Respir. Res."},{"key":"1054_CR102","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12026-020-09152-6","volume":"68","author":"D Kanduc","year":"2020","unstructured":"Kanduc, D. & Shoenfeld, Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol. Res. 68, 310\u2013313 (2020).","journal-title":"Immunol. Res."},{"key":"1054_CR103","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","volume":"20","author":"A Dotan","year":"2021","unstructured":"Dotan, A. et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 20, 102792 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1054_CR104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134189","volume":"5","author":"N Seto","year":"2020","unstructured":"Seto, N. et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight 5, e134189 (2020).","journal-title":"JCI Insight"},{"key":"1054_CR105","doi-asserted-by":"publisher","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","volume":"12","author":"K Wang","year":"2021","unstructured":"Wang, K. et al. RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1. Front. Immunol. 12, 743704 (2021).","journal-title":"Front. Immunol."},{"key":"1054_CR106","first-page":"4450","volume":"74","author":"Y Ichimura","year":"2022","unstructured":"Ichimura, Y., Konishi, R., Nomura, T., Fujimoto, M. & Okiyama, N. Autoimmunity against melanoma differentiation-associated protein 5 advances acute lung injury to interstitial lung disease in mice. Arthritis Rheumatol. 74, 4450\u20134451 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1054_CR107","doi-asserted-by":"publisher","first-page":"260","DOI":"10.55563\/clinexprheumatol\/ohsmuj","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Alterations of peripheral blood B cell subsets in Chinese patients with adult idiopathic inflammatory myopathies. Clin. Exp. Rheumatol. 40, 260\u2013266 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR108","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","volume":"46","author":"T Matsushita","year":"2019","unstructured":"Matsushita, T., Kobayashi, T., Kano, M., Hamaguchi, Y. & Takehara, K. Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease. J. Dermatol. 46, 1190\u20131196 (2019).","journal-title":"J. Dermatol."},{"key":"1054_CR109","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.jaut.2022.102831","volume":"130","author":"F Coutant","year":"2022","unstructured":"Coutant, F., Bachet, R., Pin, J. J., Alonzo, M. & Miossec, P. Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J. Autoimmun. 130, 102831 (2022).","journal-title":"J. Autoimmun."},{"key":"1054_CR110","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-019-1905-z","volume":"21","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. Arthritis Res. Ther. 21, 131 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1054_CR111","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/rheumatology\/key341","volume":"58","author":"K Wang","year":"2019","unstructured":"Wang, K. et al. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology 58, 511\u2013521 (2019).","journal-title":"Rheumatology"},{"key":"1054_CR112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-020-02397-4","volume":"23","author":"W Li","year":"2021","unstructured":"Li, W. et al. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. Arthritis Res. Ther. 23, 15 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1054_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye, Y. et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat. Commun. 13, 6458 (2022).","journal-title":"Nat. Commun."},{"key":"1054_CR114","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/rheumatology\/keab371","volume":"61","author":"T Gono","year":"2022","unstructured":"Gono, T., Okazaki, Y. & Kuwana, M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology 61, 806\u2013814 (2022).","journal-title":"Rheumatology"},{"key":"1054_CR115","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cei.12319","volume":"177","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin. Exp. Immunol. 177, 134\u2013141 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"1054_CR116","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/14397595.2016.1179861","volume":"27","author":"S Zhang","year":"2017","unstructured":"Zhang, S., Shen, H., Shu, X., Peng, Q. & Wang, G. Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. Mod. Rheumatol. 27, 122\u2013129 (2017).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR117","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng, Y., Zhang, S., Zhao, Y., Liu, Y. & Yan, B. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. Clin. Rheumatol. 37, 107\u2013115 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR118","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1097\/RHU.0000000000001772","volume":"28","author":"J Torres-Ruiz","year":"2022","unstructured":"Torres-Ruiz, J. et al. Low-density granulocytes and neutrophil extracellular traps as biomarkers of disease activity in adult inflammatory myopathies. J. Clin. Rheumatol. 28, e480\u2013e487 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"1054_CR119","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/jcmm.14858","volume":"24","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway. J. Cell Mol. Med. 24, 1658\u20131669 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"1054_CR120","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez, I. et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 93, e1193\u2013e1204 (2019).","journal-title":"Neurology"},{"key":"1054_CR121","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/14397595.2014.900843","volume":"25","author":"Y Horai","year":"2015","unstructured":"Horai, Y. et al. Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod. Rheumatol. 25, 85\u201389 (2015).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR122","doi-asserted-by":"publisher","first-page":"1151695","DOI":"10.3389\/fimmu.2023.1151695","volume":"14","author":"J Qian","year":"2023","unstructured":"Qian, J. et al. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front. Immunol. 14, 1151695 (2023).","journal-title":"Front. Immunol."},{"key":"1054_CR123","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius, C. et al. MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript. J. Invest. Dermatol. 140, 1276\u20131279.e7 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"1054_CR124","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","volume":"186","author":"Y Allenbach","year":"2016","unstructured":"Allenbach, Y. et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am. J. Pathol. 186, 691\u2013700 (2016).","journal-title":"Am. J. Pathol."},{"key":"1054_CR125","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/acn3.51311","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti\u2010MDA5 dermatomyositis. Ann. Clin. Transl. Neurol. 8, 677\u2013686 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1054_CR126","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","volume":"79","author":"I Pinal-Fernandez","year":"2020","unstructured":"Pinal-Fernandez, I. et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann. Rheum. Dis. 79, 1234\u20131242 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR127","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/rheumatology\/key386","volume":"58","author":"N Ono","year":"2019","unstructured":"Ono, N. et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology 58, 786\u2013791 (2019).","journal-title":"Rheumatology"},{"key":"1054_CR128","first-page":"275","volume":"41","author":"A Kokuzawa","year":"2023","unstructured":"Kokuzawa, A., Nakamura, J., Kamata, Y. & Sato, K. Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis. Clin. Exp. Rheumatol. 41, 275\u2013284 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR129","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel, J. et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31, 576\u2013582 (2006).","journal-title":"Clin. Exp. Dermatol."},{"key":"1054_CR130","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4049\/jimmunol.1501061","volume":"196","author":"M Sj\u00f6strand","year":"2016","unstructured":"Sj\u00f6strand, M. et al. The expression of BAFF is controlled by IRF transcription factors. J. Immunol. 196, 91\u201396 (2016).","journal-title":"J. Immunol."},{"key":"1054_CR131","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","volume":"109","author":"T Takada","year":"2015","unstructured":"Takada, T. et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis. Respir. Med. 109, 1174\u20131180 (2015).","journal-title":"Respir. Med."},{"key":"1054_CR132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2249.2012.04638.x","volume":"170","author":"M Nakano","year":"2012","unstructured":"Nakano, M. et al. Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells. Clin. Exp. Immunol. 170, 94\u2013100 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"1054_CR133","doi-asserted-by":"publisher","first-page":"1900460","DOI":"10.1183\/13993003.00460-2019","volume":"55","author":"FR Greiffo","year":"2020","unstructured":"Greiffo, F. R. et al. CX3CR1\u2013fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. Eur. Respir. J. 55, 1900460 (2020).","journal-title":"Eur. Respir. J."},{"key":"1054_CR134","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono, T. et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53, 2196\u20132203 (2014).","journal-title":"Rheumatology"},{"key":"1054_CR135","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/rheumatology\/keac627","volume":"62","author":"M Kogami","year":"2023","unstructured":"Kogami, M. et al. Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis. Rheumatology 62, 2525\u20132533 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR136","doi-asserted-by":"crossref","unstructured":"Nakatsuka, Y. et al. Serum matrix metalloproteinase levels in polymyositis\/dermatomyositis patients with interstitial lung disease. Rheumatology (Oxford) (2019).","DOI":"10.1093\/rheumatology\/kez065"},{"key":"1054_CR137","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3899\/jrheum.180825","volume":"46","author":"T Fujisawa","year":"2019","unstructured":"Fujisawa, T. et al. Clinical significance of serum chitotriosidase level in anti-MDA5 antibody\u2013positive dermatomyositis-associated interstitial lung disease. J. Rheumatol. 46, 935\u2013942 (2019).","journal-title":"J. Rheumatol."},{"key":"1054_CR138","doi-asserted-by":"publisher","first-page":"155209","DOI":"10.1016\/j.cyto.2020.155209","volume":"135","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease. Cytokine 135, 155209 (2020).","journal-title":"Cytokine"},{"key":"1054_CR139","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/rheumatology\/keaa843","volume":"60","author":"X Gui","year":"2021","unstructured":"Gui, X. et al. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis. Rheumatology 60, 3913\u20133922 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR140","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1346-8138.15589","volume":"48","author":"Y Hamaguchi","year":"2020","unstructured":"Hamaguchi, Y., Mugii, N., Matsushita, T. & Takehara, K. Long\u2010term changes in nail fold capillary abnormalities and serum fibroblast growth factor 23 levels in dermatomyositis patients with anti\u2010melanoma differentiating antigen 5 antibody. J. Dermatol. 48, 106\u2013109 (2020).","journal-title":"J. Dermatol."},{"key":"1054_CR141","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10067-021-05816-2","volume":"41","author":"L Shanshan","year":"2022","unstructured":"Shanshan, L., Yamei, Z., Ling, Z., Xin, L. & Guochun, W. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody. Clin. Rheumatol. 41, 757\u2013763 (2022).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR142","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J. Rheumatol. 44, 319\u2013325 (2017).","journal-title":"J. Rheumatol."},{"key":"1054_CR143","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","volume":"39","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol. Int. 39, 1971\u20131981 (2019).","journal-title":"Rheumatol. Int."},{"key":"1054_CR144","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","volume":"53","author":"M McPherson","year":"2022","unstructured":"McPherson, M., Economidou, S., Liampas, A., Zis, P. & Parperis, K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin. Arthritis Rheum. 53, 151959 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1054_CR145","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno, F. et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin. Arthritis Rheum. 50, 776\u2013790 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1054_CR146","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","volume":"26","author":"T Fujisawa","year":"2020","unstructured":"Fujisawa, T. et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis\u2010associated ILD : a randomized, open-label trial. Respirology 26, 370\u2013377 (2020).","journal-title":"Respirology"},{"key":"1054_CR147","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji, H. et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high\u2010dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 72, 488\u2013498 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1054_CR148","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/1346-8138.15274","volume":"47","author":"KM Matsuda","year":"2020","unstructured":"Matsuda, K. M. et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti\u2010melanoma differentiation\u2010associated gene 5 antibody\u2010positive dermatomyositis. J. Dermatol. 47, 483\u2013489 (2020).","journal-title":"J. Dermatol."},{"key":"1054_CR149","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal, R. et al. Trial of intravenous immune globulin in dermatomyositis. N. Engl. J. Med. 387, 1264\u20131278 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1054_CR150","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","volume":"61","author":"L-M Wang","year":"2022","unstructured":"Wang, L.-M. et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology 61, 3704\u20133710 (2022).","journal-title":"Rheumatology"},{"key":"1054_CR151","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","volume":"27","author":"Y Koichi","year":"2017","unstructured":"Koichi, Y. et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod. Rheumatol. 27, 536\u2013540 (2017).","journal-title":"Mod. Rheumatol."},{"key":"1054_CR152","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So, H., Wong, V. T. L., Lao, V. W. N., Pang, H. T. & Yip, R. M. L. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin. Rheumatol. 37, 1983\u20131989 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR153","doi-asserted-by":"publisher","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","volume":"172","author":"MM Mao","year":"2020","unstructured":"Mao, M. M. et al. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis\/dermatomyositis associated ILD. Respir. Med. 172, 105983 (2020).","journal-title":"Respir. Med."},{"key":"1054_CR154","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","volume":"40","author":"Y Ge","year":"2021","unstructured":"Ge, Y. et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin. Rheumatol. 40, 2311\u20132317 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR155","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa, K. et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology 57, 2114\u20132119 (2018).","journal-title":"Rheumatology"},{"key":"1054_CR156","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795","volume":"9","author":"T Ida","year":"2023","unstructured":"Ida, T. et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. 9, e002795 (2023).","journal-title":"RMD Open."},{"key":"1054_CR157","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/mrcr\/rxac049","volume":"7","author":"S Hama","year":"2023","unstructured":"Hama, S. et al. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Mod. Rheumatol. Case Rep. 7, 92\u201395 (2023).","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"1054_CR158","doi-asserted-by":"publisher","first-page":"S661","DOI":"10.1097\/RHU.0000000000001645","volume":"27","author":"Y Hosokawa","year":"2021","unstructured":"Hosokawa, Y. & Oiwa, H. A case of refractory interstitial lung disease in anti-MDA5-positive dermatomyositis that improved after switching to tofacitinib. J. Clin. Rheumatol. 27, S661\u2013s662 (2021).","journal-title":"J. Clin. Rheumatol."},{"key":"1054_CR159","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","volume":"27","author":"M Kato","year":"2021","unstructured":"Kato, M. et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J. Clin. Rheumatol. 27, S574\u2013s577 (2021).","journal-title":"J. Clin. Rheumatol."},{"key":"1054_CR160","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/RHU.0000000000002010","volume":"29","author":"S Li","year":"2023","unstructured":"Li, S. et al. Efficacy and safety of tofacitinib in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. J. Clin. Rheumatol. 29, 281\u2013284 (2023).","journal-title":"J. Clin. Rheumatol."},{"key":"1054_CR161","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen, Z., Wang, X. & Ye, S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N. Engl. J. Med. 381, 291\u2013293 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1054_CR162","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10067-023-06567-y","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis. Clin. Rheumatol. 42, 1847\u20131853 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR163","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3899\/jrheum.220367","volume":"49","author":"L Fan","year":"2022","unstructured":"Fan, L. et al. A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus. J. Rheumatol. 49, 1356\u20131364 (2022).","journal-title":"J. Rheumatol."},{"key":"1054_CR164","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","volume":"60","author":"T Le Voyer","year":"2021","unstructured":"Le Voyer, T. et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology 60, 5801\u20135808 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR165","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou, J. et al. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann. Rheum. Dis. 73, 1591\u20131593 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1054_CR166","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","volume":"60","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. Rheumatology 60, e227\u2013e228 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR167","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","volume":"163","author":"MT Holzer","year":"2023","unstructured":"Holzer, M. T. et al. Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis. Chest 163, e1\u2013e5 (2023).","journal-title":"Chest"},{"key":"1054_CR168","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1378\/chest.13-0186","volume":"144","author":"A Teruya","year":"2013","unstructured":"Teruya, A. et al. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 144, 1934\u20131936 (2013).","journal-title":"Chest"},{"key":"1054_CR169","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/qjmed\/hcv068","volume":"109","author":"MG Silveira","year":"2016","unstructured":"Silveira, M. G. et al. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM 109, 49\u201350 (2016).","journal-title":"QJM"},{"key":"1054_CR170","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","volume":"59","author":"Y Abe","year":"2020","unstructured":"Abe, Y., Kusaoi, M., Tada, K., Yamaji, K. & Tamura, N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology 59, 767\u2013771 (2020).","journal-title":"Rheumatology"},{"key":"1054_CR171","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","volume":"59","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi, M. et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology 59, 3284\u20133292 (2020).","journal-title":"Rheumatology"},{"key":"1054_CR172","doi-asserted-by":"publisher","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","volume":"133","author":"P Bay","year":"2022","unstructured":"Bay, P. et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. J. Autoimmun. 133, 102941 (2022).","journal-title":"J. Autoimmun."},{"key":"1054_CR173","doi-asserted-by":"publisher","first-page":"254","DOI":"10.55563\/clinexprheumatol\/yps7ai","volume":"40","author":"YP Ge","year":"2022","unstructured":"Ge, Y. P., Shu, X. M., He, L. R., Wang, G. C. & Lu, X. Infection is not rare in patients with idiopathic inflammatory myopathies. Clin. Exp. Rheumatol. 40, 254\u2013259 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1054_CR174","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10067-022-06403-9","volume":"42","author":"J Li","year":"2023","unstructured":"Li, J. et al. Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study. Clin. Rheumatol. 42, 453\u2013462 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1054_CR175","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","volume":"62","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis. Rheumatology 62, 3302\u20133309 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR176","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","volume":"23","author":"L Huang","year":"2021","unstructured":"Huang, L. et al. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res. Ther. 23, 232 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1054_CR177","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/rheumatology\/keab586","volume":"61","author":"L He","year":"2021","unstructured":"He, L. et al. Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease. Rheumatology 61, 345\u2013354 (2021).","journal-title":"Rheumatology"},{"key":"1054_CR178","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1093\/rheumatology\/kead034","volume":"62","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology 62, 3095\u20133100 (2023).","journal-title":"Rheumatology"},{"key":"1054_CR179","first-page":"781","volume":"382","author":"KR Flaherty","year":"2020","unstructured":"Flaherty, K. R., Wells, A. U. & Brown, K. K. Nintedanib in progressive fibrosing interstitial lung diseases. Reply. N. Engl. J. Med. 382, 781 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1054_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li, T. et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci. Rep. 6, 33226 (2016).","journal-title":"Sci. Rep."},{"key":"1054_CR181","doi-asserted-by":"publisher","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","volume":"8","author":"J Liang","year":"2021","unstructured":"Liang, J. et al. Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front. Med. 8, 626953 (2021).","journal-title":"Front. Med."},{"key":"1054_CR182","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fmed.2020.00077","volume":"7","author":"L Pacot","year":"2020","unstructured":"Pacot, L. et al. Interstitial lung disease-complicated anti-MDA5 antibody in clinically amyopathic dermatomyositis patients: report of two cases with distinct clinical features. Front. Med. 7, 77 (2020).","journal-title":"Front. Med."},{"key":"1054_CR183","first-page":"1","volume":"2021","author":"AS Jhajj","year":"2021","unstructured":"Jhajj, A. S., Shun Yeung, J. H., To, F. & Tsay, G. J. Spontaneous pneumomediastinum due to anti-melanoma differentiation-associated protein 5 requiring a bilateral lung transplant. Case Rep. Rheumatol. 2021, 1\u20134 (2021).","journal-title":"Case Rep. Rheumatol."},{"key":"1054_CR184","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.transproceed.2021.08.012","volume":"53","author":"A Marchiset","year":"2021","unstructured":"Marchiset, A. et al. High-emergency lung transplantation for interstitial lung disease associated with anti-MDA5 dermatomyositis: a case report. Transpl. Proc. 53, 2613\u20132615 (2021).","journal-title":"Transpl. Proc."},{"key":"1054_CR185","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/cpdd.887","volume":"10","author":"S Neelakantan","year":"2021","unstructured":"Neelakantan, S. et al. Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon \u03b2 monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study. Clin. Pharmacol. Drug. Dev. 10, 307\u2013316 (2021).","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"1054_CR186","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher, A. C. et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329, 2154\u20132162 (2023).","journal-title":"JAMA"},{"key":"1054_CR187","doi-asserted-by":"publisher","first-page":"7948095","DOI":"10.1155\/2020\/7948095","volume":"2020","author":"YW Shen","year":"2020","unstructured":"Shen, Y. W., Zhang, Y. M., Huang, Z. G., Wang, G. C. & Peng, Q. L. Increased levels of soluble CD206 associated with rapidly progressive interstitial lung disease in patients with dermatomyositis. Mediators Inflamm. 2020, 7948095 (2020).","journal-title":"Mediators Inflamm."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01054-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:05:26Z","timestamp":1703167526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":187,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01054-9","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"27 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}